A genomic and epigenomic lens into the biology of acute lymphoblastic leukaemia.
Genomic and epigenomic profiling reveal over 40 molecular subtypes of acute lymphoblastic leukemia, enhancing classification and informing treatment strategies.
- Why it matters: Understanding the genetic and epigenetic diversity of ALL is crucial for improving risk assessment, tailoring therapies, and overcoming treatment resistance driven by clonal evolution and adaptive reprogramming.
- What they did: The study reviews recent advances in identifying genetic alterations, gene expression, three-dimensional genome architecture, and epigenetic changes that influence ALL development and therapy response, analyzing over 40 subtypes.
- The result: Integrating these molecular insights enables better risk stratification and targeted therapies, potentially overcoming resistance and improving clinical outcomes for ALL patients.